Original Article

You have full text access to this OnlineOpen article

Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors†

  1. Brent J. Small PhD1,2,‡,*,
  2. Kerri Sharp Rawson MS1,
  3. Erin Walsh MS3,
  4. Heather S. L. Jim PhD2,
  5. Tiffany F. Hughes PhD4,
  6. Lindsay Iser MA1,
  7. Michael A. Andrykowski PhD3,
  8. Paul B. Jacobsen PhD2,5

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25685

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1369–1376, 1 April 2011

Additional Information

How to Cite

Small, B. J., Rawson, K. S., Walsh, E., Jim, H. S. L., Hughes, T. F., Iser, L., Andrykowski, M. A. and Jacobsen, P. B. (2011), Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer, 117: 1369–1376. doi: 10.1002/cncr.25685

Author Information

  1. 1

    School of Aging Studies, University of South Florida, Tampa, Florida

  2. 2

    Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, Florida

  3. 3

    Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky

  4. 4

    Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania

  5. 5

    Department of Psychology, University of South Florida, Tampa, Florida

  1. ‡

    Fax: (813) 974-9754

*School of Aging Studies, University of South Florida, 4202 E. Fowler Avenue, MHC1300, Tampa, FL 33647

  1. †

    The impact of cancer treatment on cognitive performance is an important quality-of-life outcome for cancer survivors. In this study, the authors demonstrated that breast cancer survivors who were treated with chemotherapy were at the greatest risk of cognitive impairment if they carried the catechol-O-methyltransferase Val gene.

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 30 AUG 2010
  4. Manuscript Revised: 11 AUG 2010
  5. Manuscript Received: 5 MAY 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (140K)

REFERENCES

  • 1
    Hewitt M, Greenfield SE. From Cancer Patient to Cancer Survivors. Lost in Translation. Washington, DC: National Academies Press; 2005.
  • 2
    Ahles T, Saykin A. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7: 192-201.
  • 3
    Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Support Palliat Care. 2007; 1: 57-62.
  • 4
    Jim HSL, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009; 115: 1776-1783.
    Direct Link:
  • 5
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatment for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967-982.
  • 6
    Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips K-A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cognition. 2005; 59: 60-70.
  • 7
    Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function? The Lancet Oncology. 2004; 5: 273-282.
  • 8
    Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004; 22: 2233-2239.
  • 9
    Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009; 15: 951-962.
  • 10
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612-619.
    Direct Link:
  • 11
    Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997; 278: 1349-1356.
  • 12
    Small BJ, Rosnick CB, Fratiglioni L, Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004; 19: 592-600.
  • 13
    Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging. 2009 Mar 12. [Epub ahead of print].
  • 14
    Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain and Behavior. 2006; 5: 311-328.
    Direct Link:
  • 15
    Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cog Sci. 2004; 8: 325-335.
  • 16
    Nagel IE, Chicherio C, Li SC, et al. Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci. 2008; 2: 1.
  • 17
    Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007; 25: 3866-3870.
  • 18
    Silverman DHS, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007; 103: 303-311.
  • 19
    Andrykowski MA, Burris JL, Walsh E, Small BJ, Jacobsen PB. Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls. J Clin Oncol. 2010; 28: 3442-3447.
  • 20
    Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005; 104: 2499-2507.
    Direct Link:
  • 21
    Nelson HE. The National Adult Reading Test (NART): Test Manual. Windsor, Berks, UK: NFER-Nelson; 1982.
  • 22
    Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Adult Version. San Antonio, TX: Psychological Corporation; 1987.
  • 23
    Wechsler D. Weschler Memory Scale-III Manual. San Antonio, TX: Psychological Corporation; 1997.
  • 24
    Wechsler D. WAIS-III Administration and Scoring Manual. San Antonio, TX: Psychological Corporation; 1997.
  • 25
    D'Elia LF, Satz P, Uchiyama CL, White T. Color Trails Test. Odessa, FL: Psychological Assessment Resources; 1996.
  • 26
    Benton A, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1989.
  • 27
    Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1993.
  • 28
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer. 2004; 100: 2292-2299.
    Direct Link:
  • 29
    Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006; 98: 1742-1745.
  • 30
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 1387-1397.
  • 31
    Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640-650.
    Direct Link:
  • 32
    Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979; 6: 65-70.
  • 33
    Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010; 116: 3348-3356.
    Direct Link:
  • 34
    Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006; 24: 1633-1642.
  • 35
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485-493.
  • 36
    Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003; 60: 889-896.
  • 37
    Barnett JH, Scoriels L, Munafò MR. Meta-analysis of the cognitive effects of the Catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008; 64: 137-144.
  • 38
    Guttmacher AE, Collins FS. Genetic medicine–a primer. New Engl J Med. 2002; 347: 1512-1520.
  • 39
    Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363: 301-304.
View Full Article (HTML) Get PDF (140K)